An interventional study of Menstrual cup use in Endometrial Cancer, Lynch Syndrome and Screening, sponsored by Jessica D. St. Laurent, MD. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Jessica D. St. Laurent, MD · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 715 studies in Endometrial Neoplasms with a site in United States — 195 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.
Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 445th largest by planned enrollment of the 591 interventional ones that give a count, is one of 55 that started in 2025, is one of 116 with no phase, reaches primary completion later than 96 of the 283 other live ones, and was the 651st registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →195 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, China and 2 more countries
Ages 18+ · Women only
University of Oklahoma · Sites in United States
Ages 18+ · Women only
Crescent Biopharma, Inc. · Sites in United States
Ages 18+
Sutro Biopharma, Inc. · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
715 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 277 · Phase 2 264 · Phase 3 40 · Phase 4 3
First in 1987; this study’s year is marked. 55 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 60 across the 591 interventional studies, 148 across the 100 observational. Of the 386 that completed or were terminated, 132 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 715 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jessica D. St. Laurent, MD as lead sponsor.
Jessica D. St. Laurent, MD has 1 study filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
95 of the studies in Endometrial Neoplasms with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03785288Phase 3Kara Romano, MDVaginal Cuff Brachytherapy Fractionation Study | 2027-01-30 |
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT05256225Phase 3National Cancer Institute (NCI)Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | 2027-10-31 |
| NCT02285192Memorial Sloan Kettering Cancer CenterPositron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer | 2026-11 |
Add all 95 to your calendar (.ics) → With an account.
Among the 715 studies in Endometrial Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study Goal:
This pilot study wants to find out if using a menstrual cup can be a good, non-invasive way to collect samples from the lining of the uterus (called the endometrium) to help screen for endometrial cancer. This is especially important for women who have a higher chance of getting this cancer, such as those with a genetic condition called Lynch syndrome.
Main Questions the Study Will Answer:
What Will Happen in the Study:
What the Study Will Measure:
Why This Study Matters: If this method works, it could offer a gentler, more convenient way for women to get checked for endometrial cancer-especially those who need regular screening. It could also make it easier to collect samples for research and improve early detection of cancer.
Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome (SCREEN-CUP) The study entails two parts that will be conducted one after each other.
Pre-pilot study Pre-pilot study including 5 menstruating females who will provide a one-time menstrual cup-based endometrial collection for the generation of organoids and for a pathological evaluation of endometrial specimen from menstrual fluid.
After optimizing the study protocol in the pre-pilot study period, the main study will be conducted.
Pre-pilot study
Inclusion criteria:
Exclusion criteria:
Main Study Inclusion criteria
Exclusion criteria:
Single arm study: Intervention includes use of a mentrual cup to collect menstrual fluid
Device: Menstrual cup use
Menstrual cup use in menstruating women to collect menstrual fluid with the aim to 1) compare the histology to endometrial biopsy samples from the same patient, to 2) investigate the feasibility and clinical utility of a menstrual cup use as a screening method for endometrial cancer and to 3) generate organoids from the menstrual cup samples
Proportion of samples considered adequate for pathologic evaluation
A pathologist will evaluate the menstrual cup-based sample and record its adequacy for pathological evaluation using a questionnaire with binary responses.
Time frame: Postprocedural (7-14 days after study visit #2)
Overall participant satisfaction with menstrual cup collection for endometrial screening.
Participants self-report to questions on overall participant satisfaction with menstrual cup collection for endometrial screening with 5 answer possibilities ranging from "very satisfied" to "very dissatisfied".
Time frame: Periprocedural (on day of study visit #2)
Successful endometrial organoid generation from menstrual cup sample
Successful organoid generation from menstrual cup samples will be assessed by viability assays after 5 days of culture and immunofluorescence imaging to compare cell composition.
Time frame: Postprocedural (5-7 days after study visit #2)
Successful endometrial organoid generation from endometrial biopsy sample (EMB).
Successful organoid generation from EMB samples will be assessed by viability assays after 5 days of culture and immunofluorescence imaging to compare cell composition.
Time frame: Postprocedural (5-7 days after study visit #2)
Provider satisfaction of menstrual cup collection for endometrial cancer screening within this study setting
Provider self-report on question regarding satisfaction of menstrual cup collection for endometrial cancer screening within this study setting with 5 answer possiblities ranging from "very satisfied" to "very dissatisfied".
Time frame: Through study completion, an average of 1 year.
Plan to share: Yes — De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a data use agreement. The protocol and statistical analysis plan will be made available to on clinicaltrials.gov only as required by federal regulations or as a condition of awards and agreements supporting research.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 12 months after publication of the primary results, for a period of up to 3 years.
Access criteria: Researchers must submit a methodologically sound proposal and demonstrate an IRB-approved protocol. Requests maybe directed to the sponsor investigator or designee. A formal data use agreement will be required prior to access.
Data sharing details ↗ · www.stlaurentlab.org
Started Nov 2025 (actual). Primary completion is estimated for Mar 2027, 16 months after the start.
Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 16 months is below that.
Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.